Chiasma (CHMA) is a small clinical stage biopharmaceutical company that improves orphan drugs for rare diseases. The company uses its proprietary technology known as Transient Permeability Enhancer ((TPE)) to enhance the absorption of drugs through the intestinal walls of patients. By doing this, the technology prevents the drug from being broken down by the body’s digestive enzymes. The rare disease the company aims to treat with the drug will be acromegaly, a disease that affects more than 69,000 people worldwide. In the United States, the disease affects more than 20,000 people.
Chiasma was